Zhou Ming-Sheng, Schulman Ivonne Hernandez
Division of Nephrology and Hypertension, Vascular Biology Institute, Nephrology-Hypertension Section, Veterans Affairs Medical Center and , University of Miami Miller School of Medicine, Miami, FL 33125, USA.
Vasc Health Risk Manag. 2009;5(1):361-8. doi: 10.2147/vhrm.s4331.
A growing number of experimental and clinical studies have provided evidence indicating that pharmacological blockade of the renin-angiotensin system (RAS) by either angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers reduces the incidence of new onset type 2 diabetes in subjects with hypertension and/or cardiovascular disease, independently of antihypertensive and cardiovascular protective effects. The beneficial effects of RAS inhibition on the development of diabetes have been largely attributed to improvements in peripheral insulin sensitivity and glucose metabolism. This review focuses on recent experimental and clinical evidence supporting the role of RAS inhibition in the reduction of new onset type 2 diabetes and the mechanisms that may be involved.
越来越多的实验和临床研究提供了证据，表明通过血管紧张素转换酶抑制剂或1型血管紧张素受体阻滞剂对肾素-血管紧张素系统（RAS）进行药物阻断，可降低高血压和/或心血管疾病患者新发2型糖尿病的发生率，这与降压和心血管保护作用无关。RAS抑制对糖尿病发生发展的有益作用很大程度上归因于外周胰岛素敏感性和葡萄糖代谢的改善。本综述重点关注支持RAS抑制在降低新发2型糖尿病中作用的近期实验和临床证据以及可能涉及的机制。
